ROCKVILLE, Md. - Wednesday, June 3rd 2015 [ME NewsWire]
(BUSINESS WIRE)-- Trophogen, Inc. today announced that the company has completed a licensing and purchase agreement granting Zoetis, Inc., the leading global animal health company, an exclusive license to develop Trophogen’s recombinant modified bovine Follicle-Stimulating Hormone (rbFSH) analog in the field of animal health reproduction. Under the terms of the agreement, the recombinant long-acting bovine FSH superagonist analog will be evaluated and developed for its potential use in superovulation and embryo transfer in beef and dairy cows.
“We believe Trophogen’s proprietary recombinant technology will make possible the development of uniquely differentiated FSH proteins that will significantly impact the reproduction management of cattle and other animals,” said Trophogen’s President and Chief Executive Officer, Bruce Weintraub, M.D. “We are quite privileged to have Zoetis as the development partner conducting additional clinical field trials given the company’s deep expertise and diverse portfolio of livestock reproductive products. We look forward to exploring the potential of this product with them to bring innovative recombinant biologics to animal reproduction and value to the veterinary industry.”
Terms of the agreement were not disclosed.
About Trophogen, Inc.
Trophogen, Inc. is a U.S.-based biotechnology company founded in 2001 with Series A funding from Toucan Capital, in late stage preclinical focusing on development of human and bovine high affinity glycoprotein hormone and related growth factor superagonist analogs which are long-acting, more potent and efficacious, for human infertility, animal superovulation, wound healing as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers. Trophogen has also received over $10 million from 10 NIH and FDA small business SBIR grants to take other advanced pre-clinical human products to Phase I-II clinical trials by 2016-2017 for additional multibillion dollar markets. It has also received over $4 million from various human and veterinary pharmaceutical co-development and licensing agreements. For more information about Trophogen, please visit www.trophogen.com.
Trophogen, Inc. 9714 Medical Center Dr., Suite 1114 Rockville, MD 20850
Contacts
Trophogen, Inc.
Alex Usog
Director of Operations
ph: 301-838-1935 x1101
fx: 301-762-6287
ausog@trophogen.com
Permalink: http://www.me-newswire.net/news/14800/en
(BUSINESS WIRE)-- Trophogen, Inc. today announced that the company has completed a licensing and purchase agreement granting Zoetis, Inc., the leading global animal health company, an exclusive license to develop Trophogen’s recombinant modified bovine Follicle-Stimulating Hormone (rbFSH) analog in the field of animal health reproduction. Under the terms of the agreement, the recombinant long-acting bovine FSH superagonist analog will be evaluated and developed for its potential use in superovulation and embryo transfer in beef and dairy cows.
“We believe Trophogen’s proprietary recombinant technology will make possible the development of uniquely differentiated FSH proteins that will significantly impact the reproduction management of cattle and other animals,” said Trophogen’s President and Chief Executive Officer, Bruce Weintraub, M.D. “We are quite privileged to have Zoetis as the development partner conducting additional clinical field trials given the company’s deep expertise and diverse portfolio of livestock reproductive products. We look forward to exploring the potential of this product with them to bring innovative recombinant biologics to animal reproduction and value to the veterinary industry.”
Terms of the agreement were not disclosed.
About Trophogen, Inc.
Trophogen, Inc. is a U.S.-based biotechnology company founded in 2001 with Series A funding from Toucan Capital, in late stage preclinical focusing on development of human and bovine high affinity glycoprotein hormone and related growth factor superagonist analogs which are long-acting, more potent and efficacious, for human infertility, animal superovulation, wound healing as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers. Trophogen has also received over $10 million from 10 NIH and FDA small business SBIR grants to take other advanced pre-clinical human products to Phase I-II clinical trials by 2016-2017 for additional multibillion dollar markets. It has also received over $4 million from various human and veterinary pharmaceutical co-development and licensing agreements. For more information about Trophogen, please visit www.trophogen.com.
Trophogen, Inc. 9714 Medical Center Dr., Suite 1114 Rockville, MD 20850
Contacts
Trophogen, Inc.
Alex Usog
Director of Operations
ph: 301-838-1935 x1101
fx: 301-762-6287
ausog@trophogen.com
Permalink: http://www.me-newswire.net/news/14800/en
No comments:
Post a Comment